Boston, MA 06/05/2014 (wallstreetpr) – Provectus Biopharmaceuticals Inc (NYSEMKT:PVCT) took a decision on May 12, 2014 to appoint Brendan O’Brien and on May 21, 2014, to appoint Jacob M. Plotsker as incumbent members of the company’s strategic advisory board.
CEO’s Take On The Incumbent Advisory Board Members
The inception of Brendan O’Brien and Jacob M. Plotsker into the board were unanimous decisions and the CEO of Provectus Biopharmaceuticals Inc (NYSEMKT:PVCT), Dr. Craig Dees humbly pointed out that the company would be richly benefited with the expertise and knowhow that the duo possesses. Further, he stated that both Brendan O’Brien and Jacob M. Plotsker would add real experience to the strategies and plans that PVCT takes, in the upcoming days. The inclusions are surely deemed to boost the strategies adopted by the company throughout the regulatory processes, to field for PV-10 and bolster its marketing activities.
PVCT Made Two Presentations In The ASCO Summit
On June 03, 2014, PVCT announced that the data on the myriad researches and investigations carried out with PV-10 to treat varied intraregional issues – detection and curing patients suffering from solid tumors, were presented in twice. PVCT depicted the power of PV-10 to treat solid tumors in the presentations in a Poster Highlights Session for Melanoma/Skin Cancer, held during the ASCO Annual Summit in Chicago, on June 02, 2014.
Pomerantz LLP Files A Lawsuit
On May 29, 2014, Pomerantz LLP filed a Class-Action Lawsuit against Provectus Biopharmaceuticals Inc (NYSEMKT:PVCT) and a few of its officers. The lawsuit was filed in the US District Court of the Middle District-Tennessee, Nashville unit, on behalf of entities and individuals who purchased or acquired PVCT’s securities during December 17, 2013 and May 22, 2014. The lawsuit seeks to duly recover myriad instances of damages done against the class of entities for violations of the Federal Securities Laws – Sections 10(b), 20(a) of the Securities Exchange Act (1934) and another Rule 10b-5, that was promulgated thereafter.
PVCT’s Violations And Consequential Price Drop
The violations constitute alleged payments doled out to stock promoters to foster inflation of PVCT’s share price, misrepresentations confirming rigorous study of PV-10 Phase 3 – which was never started and thirdly, reinstating the PV-10 has obtained Breakthrough Therapy Designation, which never happened! Provectus Biopharmaceuticals Inc (NYSEMKT:PVCT) has denied these allegations, however, the traders seemed miffed – consequently, share prices went down, thick and fast!
